EMEA-002243-PIP01-17

Key facts

Active substance
Eptinezumab
Therapeutic area
Neurology
Decision number
P/0314/2019
PIP number
EMEA-002243-PIP01-17
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Prevention of migraine headaches
Route(s) of administration
Intravenous use
Contact for public enquiries
Alder BioPharmaceuticals Limited

Tel: +1 4252052900
E-mail: info@alderbio.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating